Skip to content

Study for the Effect of Huamoyan Keli Combined with Diacerein Capsule on Cytokines in Knee Osteoarthritis

Study for the Effect of Huamoyan Keli Combined with Diacerein Capsule on Cytokines in Knee Osteoarthritis

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018531
Enrollment
Unknown
Registered
2018-09-22
Start date
2018-11-01
Completion date
Unknown
Last updated
2018-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis

Interventions

Group 1:Application of Huamoyan Keli
Group 2:Application of Huamoyan Keli combined with Diacerein capsule
Group 3:Placebo group

Sponsors

Department of Orthopaedics, the second Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. in accordance with the diagnostic criteria for knee osteoarthritis; 2. in accordance with the diagnostic criteria for hydrops of the knee established by the WTO: (1) There is swelling and pain in the joints; (2) Ultrasonic examination of joint effusion and exclusion of systemic swelling disease(Ultrasonography showed that the anechoic effusion in femur and tibia was higher than that of 0.3cm in both femur and tibia); (3) X-ray examination of widening of joint space and indication of effusion; (4) Hydrops have been extracted from previous treatments; (5) Floating patellar test positive; (6) Have been diagnosed with related diseases such as hyperosteogeny, rheumatism, rheumatoid disease, tuberculosis, trauma; 3. aged = 40 years male and female; 4. agreeing to participate in the clinical trial and sign the informed consent form voluntarily; 5. having good tolerance to the drug treatment needed in this study, without related contraindication; 6. No clinical treatment was received in the first month of the study.

Exclusion criteria

Exclusion criteria: 1. Arthritis of the knee caused by rheumatoid arthritis, traumatic arthritis, gouty arthritis, tuberculosis or allergies; 2. Associated with infection, fracture, dislocation, ligament rupture, pigmented villonodular synovitis, hemophilic arthritis and other diseases that can cause joint pain, swelling and dysfunction; 3. With heart, liver, kidney, hematopoietic system and other important organ diseases; 4. History of substance abuse, alcohol abuse or mental illness; 5. Pregnant and lactating women and recent family planning; 6. Allergy to known ingredients and allergy constitution of the test drugs; 7. Other clinical trials were conducted during the first month of the study; 8. the researchers did not consider it appropriate to participate in this study.

Design outcomes

Primary

MeasureTime frame
WOMAC scale;

Countries

China

Contacts

Public ContactZhiyong Fan

The second Hospital of Hebei Medical University

fanzy72@126.com+86 13333013721

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026